Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:ticagrelor
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
B01AC24
|
| gptkbp:chemicalFormula |
C23H28F2N6O4S
|
| gptkbp:contraindication |
active bleeding
history of intracranial hemorrhage |
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brilique
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
P2Y12 receptor antagonist
|
| gptkbp:otherName |
gptkb:ticagrelor
gptkb:Brilinta |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
bleeding
dyspnea |
| gptkbp:usedFor |
gptkb:acute_coronary_syndrome
myocardial infarction |
| gptkbp:bfsParent |
gptkb:ticagrelor
gptkb:Brilinta |
| gptkbp:bfsLayer |
6
|